Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

  • Paths of Progress Spring/Summer 2015

    Know Your Surroundings banner 

    What help do tumors get from cells around them, and how can treatments stop that support?

    by Eric Bender

    Multiple myeloma is a poster child for recent advances in treatment: In the past decade, the U.S. Food and Drug Administration (FDA) approved no fewer than nine treatments for the blood cancer, and several more drug approvals appear to be near. Not coincidentally, multiple myeloma is also a popular target that researchers use to study the interactions of tumor cells and their "tumor microenvironments" — the non-cancerous cells, molecules and blood vessels that surround and often support the malignant cells.

    "These new myeloma drugs are all based on understanding how the tumor cells interact with other cells in their bone marrow environment,” says Kenneth Anderson, MD, director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC).

    Many labs studying numerous other cancers are also now targeting tumor microenvironments, hoping to replicate dramatic progress against multiple myeloma.

    Managing Myeloma

    Multiple myeloma begins with mutations in the development of B cells — white blood cells that can turn into plasma cells that normally fight bacteria or viruses. The first clinical sign is a condition called monoclonal gammopathy of undetermined significance (MGUS), with abnormal plasma cells appearing in the bone marrow.

    A small fraction of people with MGUS progress to smoldering myeloma, displaying higher populations of these cells. Most people with smoldering myeloma eventually develop active multiple myeloma, with low blood counts and increased risk of infection, kidney dysfunction, high blood calcium, and painful bone lesions.

    Throughout the course of this disease, the interaction of these mutated plasma cells with their microenvironment is critically important.

    "It's called cell-adhesion mediated drug resistance, because binding of the tumor cell to the bone marrow triggers pathways mediating myeloma cell growth, survival and drug resistance," Anderson says. "The novel agents overcome the conventional drug resistance that's conferred by the microenvironment."

    Numerous types of nearby cells may be enlisted to aid the tumor, and thus may be targets for new agents. One example is plasmacytoid dendritic cells (pDCs), which normally alert the immune system to respond to a suspicious cell.

    Irene Ghobrial quote  

    "In myeloma these pDCs do not stimulate immune responses as they should, and even worse, they promote tumor cell growth and drug resistance," says Anderson. "So we are utilizing agents that target these pDC cells as potential myeloma therapies. In our models, we can use targeted treatments to mature these cells so they no longer promote tumor cells and acquire the ability to stimulate immune responses as they should. This result needs to be validated in clinical trials, but it's another proof-of-principle that the microenvironment really matters."

    In another project reported in 2014, researchers led by Irene Ghobrial, MD, demonstrated that in mice, an agent that blocked a protein known as stromal cell derived factor-1 (SDF-1), which is present in high levels in areas of the bone marrow with myeloma lesions, slowed the spread of the cancer and improved survival.

    With this and many other research projects underway in her lab, "the whole idea is to reverse the way we think – instead of treating patients later on when the disease has progressed, can we change the microenvironment to prevent progression?" Ghobrial emphasizes. "We're designing trials now to take the best drugs we have and bring them earlier to smoldering disease."

    Kenneth Anderson, MD, Irene Ghobrial, MD, and Kornelia Polyak MD, PhDDana-Farber's Kenneth Anderson, MD (top), Irene Ghobrial, MD (lower left), and Kornelia Polyak MD, PhD (lower right), each explore different aspects of the tumor microenvironment — the molecules, cells, and blood vessels that surround and support a tumor. 

    Stromal Surroundings

    Tumor microenvironments are studied broadly and deeply in other blood cancers, and in many solid tumors as well. "In breast cancer, there's a lot of data showing that the microenvironment is really important for tumor progression and for therapeutic resistance," says Kornelia Polyak, MD, PhD, a breast cancer geneticist at DF/BWCC.

    Breast cancer cells are surrounded by a "stroma" composed mostly of fibroblasts (the most common connective tissue cell), blood vessels, and immune system cells. "The stroma frequently makes the cancer cells more resistant to treatment," says Polyak.

    In one line of microenvironment research, Polyak's lab is focusing on the role of fibroblasts from primary breast tumors and metastatic sites such as brain lesions that tend to be particularly resistant to treatment.

    Other work examines the role of immune system cells in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer. In normal breast tissue, these immune system cells go into the duct, but something stops them in DCIS so the tumor grows without interference from the immune system, she notes.

    A third project looks at "myoepithelial" cells, which produce the barrier of connective tissue supporting breast ducts but tend to disappear as DCIS progresses.

    Common Across Cancers

    Despite all the obvious differences between breast cancer and multiple myeloma, researchers stress that the two diseases, and many other cancers, share many of the same molecular signaling pathways. "Learning about the biology from each other will be very significant," Anderson says.

    One key theme across cancers is the role of the microenvironment in metastasis, the spreading of cancer to additional parts of the body. For example, tumor cells secrete "exosomes", tiny packages of protein and RNA that may help to seed metastases. Demonstrated in breast cancer, this phenomenon has been hypothesized to occur in myeloma as well. "Maybe that's why we start getting all those myeloma lesions growing fast at the same time," Ghobrial speculates.

    Another common theme is the hope that drugs targeting the microenvironment may not need to be as selective as targeted drugs that seek out very specific mutations in tumor cells. Since the microenvironmental cells aren't mutated, each type can be attacked as a population and it can't develop resistance to drugs.

    "If you look at the successful treatments in myeloma, they are not mutation-specific," Ghobrial points out. For instance, proteasome inhibitors such as Velcade, which block the breakdown of proteins so that cells fill up with molecular garbage and die, "just kill any plasma cell," she says.

    "If you think about treatments for myeloma or breast cancers or other tumors directed against intrinsic abnormalities in the cancer cell, that gives you a number of opportunities," Anderson sums up. "But if you target the host microenvironment or the interaction of the tumor with the microenvironment, you broadly expand the therapeutic options available."

    Paths of Progress Spring/Summer 2015 Table of Contents 

  •   Email
  •   Print
  •   Share